BLOG

Pepinemab Clinical Trial Ongoing; Top-line Results Coming Later this Year

Vaccinex’s Phase 2 SIGNAL study, evaluating the investigational antibody pepinemab (VX15/2503) in Huntington’s disease patients with late prodromal and early disease, is ongoing and has tested pepinemab in all 265 patients enrolled in cohort B, the company announced.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}